Human Immunology News

[Scientific Reports] Scientists validated the previous finding by Western blotting and immunohistochemistry on primary retinoblastoma (RB) tumor samples. The results suggested significantly increased expression of B7H3 in RB tumor samples compared to retina by western blotting.

[Molecular Cell] The authors explore current strategies that shift immune cell metabolism to pro-inflammatory states in the tumor microenvironment and highlight a need to better replicate physiologic conditions to select targets, clarify mechanisms, and optimize metabolic inhibitors.

[Signal Transduction and Targeted Therapy] The authors discuss the potential of anti-neurogenesis and, considering the interplay between nervous and immune systems, they also focus on anti-immunosuppression-based therapies.

[Univesity of California, Los Angeles] University of California, Lost Angeles (UCLA) researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.

[Trends in Pharmacological Sciences] Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for cytokine release syndrome, which is a common cause of adverse clinical outcomes in COVID-19.

[Experimental and Molecular Medicine] Scientists investigated a novel role for transglutaminase 2 (TGM2) in the development of tumor-promoting inflammation and recruitment of tumor-associated macrophages to gastric cancer (GC) tissues. When estimated by array comparative genomic hybridization and droplet digital PCR, the copy numbers of the TGM2 gene were amplified in 13.6% of GC patients and positively associated with TGM2 expression.